Colistine pharmacokinetics and Colistimethate sodium daily dose calculation in children with chemotherapy induced neutropenia
https://doi.org/10.17650/1818-8346-2014-9-2-53-57
Abstract
A standard fractional Colistimethate sodium dosing regimen does not allow in most cases reach the target values of AUC / MIC index, determining the Colistine pharmacological efficacy. Use of the proposed algorithm for daily dose calculating increases the incidence to achieve Colistine concentration providing AUC values, sufficient for A. baumannii, P. aeruginosa and K. pneumoniae with Colistine MIC
0.75–1 mg / l. Using fractional administration of recommended daily dose target AUC values for MIC 1 g / l achieved only in 19 % cases,
whereas using the proposed algorithm of intravenous injection with long-time constant rate of daily dose 100.000 ME / kg Colistimethate
sodium – in 60 % (in 3 of 5 patients).
About the Authors
V. I. Zakharevich
Republican Scientific Centеr of Pediatric Oncology, Hematology and Immunology, Ministry of Health of Republic of Belarus, Minsk
Russian Federation
Russian Federation
V. V. Dmitriev
Republican Scientific Centеr of Pediatric Oncology, Hematology and Immunology, Ministry of Health of Republic of Belarus, Minsk
Russian Federation
Russian Federation
References
1. Giamarellou H., Antoniadou А. Antipseudomonal antibiotics. Med Clin N Am 2001;85:19–42.
2. Evans M. E., Feola D. J., Rapp R. P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram- negative bacteria. Ann Pharmacother 1999;33:960–7.
3. Barnett M., Bushby S. R., Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol 1964;23:552–74.
4. Schwartz B. S., Warren M. R., Barkley F. A. Landis L. Microbiological and pharmacological studies of colistin sulphate and sodium colistin methanesulfonate. Antibiotics Annu 1959–1960;7:41–60.
5. Li J., Turnidge J., Milne R. et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:781–5.
6. Li J., Milne R. W., Nation R. L. et al. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002;46(10):3304–7.
7. Li J., Coulthard K., Milne R. et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003;52:987–92.
8. Bergen P. J., Li J., Rayner C. R. et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953–8.
9. Gobin P., Lemaitre F., Marchand S. et al. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography tandem mass spectrometry. Antimicrob Agents Chemother 2010;54(5):1941–8.
10. Dotsikas Y., Markopoulou C. K., Koundourellis J. E. et al. Validation of novel LC–MS / MS method for the quantitation of cilistin A and B in human plasma. J Sep Sci 2011;34:37–45.
11. Gobin P., Lemaître F., Marchand S. et al. Stability of colistimethate sodium in aqueous solution. Antimicrob Agents Chemother 2012;56(12):6432–3.
12. Bergen P. J., Li J. Nation R. L. Dosing of colistin – back to basic PK / PD. Curr Opin Pharmacol 2011;11(5):464–9.
Review
For citations:
Zakharevich V.I., Dmitriev V.V. Colistine pharmacokinetics and Colistimethate sodium daily dose calculation in children with chemotherapy induced neutropenia. Oncohematology. 2014;9(2):53-57. (In Russ.) https://doi.org/10.17650/1818-8346-2014-9-2-53-57
Views:
10126
Email this article 